Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study
- Wednesday, December 9, 2020, 7:02
- Finance
- Add a comment
MONMOUTH JUNCTION, N.J., Dec. 9, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world,…
About the Author
adminasapcorp has written 41811 stories on this site.